Lipocine appoints Jill M. Jene and Spyros Papapetropoulos to board of directors
Lipocine Inc.
Board expanded to six members; Dr. Jene and Dr. Papapetropoulos appointed effective April 11, 2022.
Both are independent directors under Nasdaq rules; Dr. Jene will serve on Audit Committee, Dr. Papapetropoulos on Compensation Committee.
Each new director receives an initial option grant for 10,000 shares and $35,000 annual retainer plus $5,000 for committee service.
Dr. Jene brings over 20 years of biopharma strategy and deal-making; Dr. Papapetropoulos has neuroscience expertise and experience as CMO at multiple firms.
On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.
On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Jill M. Jene was appointed as Director at Lipocine Inc..
Action
appointed
Role
Director
Exact text from the filing
On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.
Spyros Papapetropoulos was appointed as Director at Lipocine Inc..
Action
appointed
Role
Director
Exact text from the filing
On April 11, 2022, the Board of Directors of the Company expanded the Board of Directors to six members and appointed Dr. Jill M. Jene and Dr. Spyros Papapetropoulos as directors, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.